Gotham Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Gotham Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19,081	Closed	-$451K	–	1479
2023 Q4	$451K	Sell	19,081 -21,381	-53%	-$381K	0.01%	1023
2023 Q3	$603K	Buy	+40,462	New	+$536K	0.01%	924

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Gotham Asset Management's CBAY Position: Q1 2024 in Review

Gotham Asset Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 19,081 shares — an estimated $451K sold.

Gotham Asset Management first reported a position in CBAY in Q3 2023 and held it in 2 quarters. The position peaked at $603K in Q3 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Gotham Asset Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Gotham Asset Management sold 19,081 Cymabay Therapeutics shares in Q1 2024, an estimated $451K.
Gotham Asset Management first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 2 quarters.
Gotham Asset Management's Cymabay Therapeutics position peaked at $603K in Q3 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Gotham Asset Management's 13F filing for Q1 2024, filed 15 May 2024.